ClinicalTrials.gg
Active, not recruitingNCT05210868Updated Jan 27, 2022

A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase 1/2 interventional study of CM355 in Hematoma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
184
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Hematoma with a site in China — 2 open to participants now, 3 under way, none of them phase 3. Hematoma · China.

Started
2021
with 2 others
Phase 1/2
Only one
of the 10
Registered
4th of 10
by date
Lead sponsor
1 of 10
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 10 studies in Hematoma with a site in China, this one is one of 3 that started in 2021, is the only one in phase 1/2, and was the 4th registered.

Hematoma

109 studies on the registry are indexed under Hematoma; 19 are open to participants now.

Browse Hematoma studies →

Open to participants now

2 of the 10 studies in Hematoma with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hematoma studies recruiting now, 9 (90%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hematoma with a site in China, or all of them as a file.
02

Study summary

A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL

Read the detailed description

This is a phase I/II open-label, single-arm, multicenter study in China to evaluate the safety, tolerability, and efficacy of CM355 in patients with R/R B-NHL. In the study, patients will not be screened for CD20 expression, but they must have a diagnosis of B-NHL that is expected to express CD20. After enrollment, tumor samples will be collected for retrospective analysis of CD20 expression

03

Conditions studied

  • Hematoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years old.
  2. (ECOG, see Appendix 3) PS score of 0-1.
  3. Histopathologically confirmed B-cell NHL has been confirmed or anticipated to express CD20 in lymphoma lesions.
  4. According to Lugano criteria, imaging evaluation shows at least one bidimensionally .
  5. The level of organ function of patients must In line with the testing standard of the clinical trial center prior to the first dose of the drug
  6. Expected survival ≥ 3 months.
  7. All toxicities caused by prior anticancer therapy must have recovered to grade ≤ 1 (based on v5.0) except alopecia and fatigue.
  8. Female patients with should have a negative blood pregnancy test result within 7 days prior to the first dose.
  9. Female patients with childbearing potential or male patients and their partners must agree to take effective measures from the signing of the ICF to at least 6 months after the last dose of investigational drug.
  10. Female patients cannot breastfeed or plan to become pregnant during the study until at least 6 months after the last dose of investigational drug.
  11. The patient voluntarily joined the study and signed the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Active or past central nervous system (CNS) lymphoma.
  2. Other active occurring within 5 years prior to the first dose of drug, with the exception of radically treated local curable cancers.
  3. The patient has a disease or medical history that needs to be excluded as specified in the Clinical Trial Protocol.
  4. Any active infection requiring systemic therapy via intravenous infusion within 14 days prior to the first dose of investigational drug.
  5. According to the trial scheme, patients infected with virus, virus, , EBV, CMV, syphilis, or patients with active pulmonary tuberculosis or history of pulmonary tuberculosis infection are not suitable to participate in the study.
  6. Any severe or uncontrolled systemic disease.
  7. History of severe allergic reactions ( v5.0 classification is greater than 3 grades) to humanized monoclonal antibodies, or known to any component of CM355.
  8. Any mental or cognitive disorder that may limit the patient's understanding and execution of the ICF and compliance with the study.

    Medication history and surgical history:

  9. Having received hematopoietic stem cell transplantation or received auto-HSCT within 100 days prior to the first dose.
  10. Active bleeding within 2 months prior to screening, or receiving anticoagulants, or other bleeding symptoms requiring medical intervention.
  11. Having undergone major surgery within 28 days prior to the first dose, or minor surgery within 2 weeks prior to the first dose; invasive examinations for the purpose of diagnosis are not considered as surgery; except for the insertion of vascular access device.
  12. Patients who experienced grade ≥ 3, severe or life-threatening immune-related adverse events or grade 1-2 immune-related adverse events that did not return to baseline levels after treatment discontinuation in a previous immunotherapy.
  13. Patients who have received any other investigational anti-cancer drug therapy within 28 days prior to the first dose.
  14. Inoculation of within 28 days prior to the first dose, or anticipation that live attenuated vaccines will be required during the study.
  15. Patients who have received any drugs therapy that need to be excluded from the Clinical Trial Protocol within a certain period of time for the first administration.
  16. Prior participation in other clinical trials within 28 days prior to the first dose of the investigational drug, or planning to participate in this study and other clinical trials at the same time.
  17. Known alcoholism or drug abuse history.
  18. Other conditions determined by the investigator that render patients unsuitable for participation in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
184 participants (estimated)

Study arms

  • Experimental
    CM355

    1. Dose Escalation Phase CM355 2. Dose Expansion Phase CM355

    Drug: CM355

Interventions

  • DrugCM355

    1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the "3+3" dose escalation scheme 2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLT)

    Incidence, nature, and severity of dose-limiting toxicities.

    Time frame: Up to 2 year

  2. Recommended phase II dose (RP2D) and/or (maximum tolerated dose) MTD

    To determine the recommended phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of CM355 in patients with R/R B-NHL.

    Time frame: Up to 2 year

  3. Objective response rate(ORR)

    Objective response rate (ORR) as assessed by independent review committee (IRC)

    Time frame: through study completion,an average of 5 year

  4. The safety and tolerability of CM355

    Incidence, nature, and severity of adverse events (AEs) as judged according to NCI-CTCAE v5.0.

    Time frame: through study completion,an average of 5 year

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Dose Escalation peak plasma concentration (ng/mL)

    Time frame: Every cycle (21 days), until the end of treatment

  2. Area under the plasma concentration versus time curve (AUC)

    Dose Escalation AUC(μg·h/mL)

    Time frame: Every cycle (21 days), until the end of treatment

  3. Peak time

    Time of maximum observed plasma concentration (Tmax)

    Time frame: Every cycle (21 days), until the end of treatment

  4. T1/2

    Terminal half-life of CM355

    Time frame: Every cycle (21 days), until the end of treatment

  5. Clearanc (CL)

    Total body clearance of the drug from plasma (CL) of CM355

    Time frame: Every cycle (21 days), until the end of treatment

  6. Anti-CM355 antibodies (ADAs)

    Incidence of anti-CM355 antibodies (ADAs) and their correlation with clinical outcomes.

    Time frame: Every cycle (21 days), until the end of treatment

  7. Objective response rate (ORR)

    Objective response rate (ORR) as assessed by investigators

    Time frame: through study completion,an average of 5 year

  8. Complete response rate (CRR)

    Complete response rate (CRR) as assessed by investigators or independent review committee (IRC)

    Time frame: through study completion,an average of 5 year

  9. Duration of response (DOR)

    Duration of response (DOR) as assessed by investigators or Independent review committee (IRC)

    Time frame: through study completion,an average of 5 year

  10. Progression-Free-Survival (PFS)

    Progression-Free-Survival (PFS) as assessed by investigators or independent review committee (IRC)

    Time frame: through study completion,an average of 5 year

  11. overall survival (OS)

    overall survival (OS) as assessed by investigators or independent review committee (IRC)

    Time frame: through study completion,an average of 5 year

Other outcomes

  1. Cytokines

    To conduct qualitative and quantitative analyses of the level of changes in cytokines (IL-2, IL-6, IL-10, INF-γ, and TNF-α).

    Time frame: Up to 17 cycles (21 days per cycle)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Jan 27, 2022
StartActual
Nov 16, 2021
Primary completionEst.
Dec 28, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05210868
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Nov 16, 2021
Primary completion
Dec 28, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 27, 2022

Study contacts

Yuqin Song, M.D.
principal investigator · Beijing university cancer hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion